Your browser doesn't support javascript.
loading
Influence of hormones in multiple sclerosis: focus on the most important hormones.
Soleimani, Alireza; Ezabadi, Sajjad Ghane; Möhn, Nora; Esfandabadi, Zahra Moghimi; Khosravizadeh, Zahra; Skripuletz, Thomas; Azimzadeh, Maryam.
Afiliación
  • Soleimani A; Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Ezabadi SG; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Möhn N; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Esfandabadi ZM; Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Khosravizadeh Z; Clinical Research Development Unit, Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran.
  • Skripuletz T; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Azimzadeh M; Department of Medical Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran. maryam.azimzade@khomeinums.ac.ir.
Metab Brain Dis ; 38(3): 739-747, 2023 03.
Article en En | MEDLINE | ID: mdl-36595158
ABSTRACT
Hormonal imbalance may be an important factor in the severity of multiple sclerosis (MS) disease. In this context, hormone therapy has been shown to have immunoregulatory potential in various experimental approaches. There is increasing evidence of potentially beneficial effects of thyroid, melatonin, and sex hormones in MS models. These hormones may ameliorate the neurological impairment through immunoregulatory and neuroprotective effects, as well as by reducing oxidative stress. Expanding our knowledge of hormone therapy may be an effective step toward identifying additional molecular/cellular pathways in MS disease. In this review, we discuss the role of several important hormones in MS pathogenesis in terms of their effects on immunoregulatory aspects and neuroprotection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Melatonina / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Metab Brain Dis Asunto de la revista: CEREBRO / METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Melatonina / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Metab Brain Dis Asunto de la revista: CEREBRO / METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Irán